60.22
Corcept Therapeutics Inc stock is traded at $60.22, with a volume of 536.01K.
It is up +0.89% in the last 24 hours and up +29.31% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$59.69
Open:
$60
24h Volume:
536.01K
Relative Volume:
0.32
Market Cap:
$6.46B
Revenue:
$769.10M
Net Income/Loss:
$46.67M
P/E Ratio:
172.06
EPS:
0.35
Net Cash Flow:
$119.79M
1W Performance:
+6.83%
1M Performance:
+29.31%
6M Performance:
-22.09%
1Y Performance:
-20.86%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CORT
Corcept Therapeutics Inc
|
60.22 | 6.41B | 769.10M | 46.67M | 119.79M | 0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Affiliate of CORT (NASDAQ: CORT) files Form 144 to offer 5,000 shares - Stock Titan
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade - Yahoo Finance UK
Corcept Therapeutics Inc. (CORT) Stock Analysis: Exploring a 40.15% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Corcept (CORT) chief business officer reports 7,300-share gift of common stock - Stock Titan
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
UBS upgrades Corcept Therapeutics (CORT) - MSN
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% - GuruFocus
Corcept Therapeutics Shares Rise After UBS Upgrade - Moomoo
UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72 - Moomoo
Corcept Therapeutics climbs on UBS upgrade - MSN
Corcept Therapeutics (CORT) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised - MSN
Vanguard Group Inc. Has $330.42 Million Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Stock Is Sinking Now - TipRanks
CORT IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
CORT FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS DataHas The Bull Case Changed? - Yahoo Finance
Corcept (CORT) Q1 2025 Earnings Transcript - AOL.com
Corcept Must Face Most Teva Mifepristone Antitrust Claims - Law360
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
How many employees work at Corcept Therapeutics? - Revelio Labs
Teva's US exclusive-dealing claims survive Corcept's move to dismiss - MLex
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - Yahoo Finance
Corcept (CORT) Q1 2026 Earnings Transcript - AOL.com
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Corcept (CORT) Q2 2025 Earnings Transcript - AOL.com
Corcept (CORT) Q4 2025 Earnings Transcript - AOL.com
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics Inc. (CORT) Stock Analysis: A 36.91% Upside Potential In Biotech - DirectorsTalk Interviews
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):